NICE Expands ALK’s Allergy Tablets to UK Children in Landmark Recommendation
Event summary
- NICE recommends ALK’s ITULAZAX® for children aged 5–17 with birch pollen allergy and ACARIZAX® for ages 5–11 with house dust mite allergy.
- Recommendations extend prior NICE approvals for adults (ITULAZAX® in August 2025, ACARIZAX® in March 2025) to pediatric use via NHS.
- Final Guidance expected late August 2026; NHS implementation required across England, Wales, and Northern Ireland.
- SMC previously accepted ACARIZAX® for severe house dust mite allergy in Scotland.
The big picture
NICE’s recommendations mark a strategic shift in pediatric allergy management, aligning with the UK’s National Allergy Strategy. The approvals come amid worsening allergy seasons due to climate change, positioning ALK as a key player in long-term allergy solutions. With both tablets now approved for all ages, ALK strengthens its market position in sublingual immunotherapy.
What we're watching
- Market Expansion
- Whether ALK can sustain momentum in pediatric allergy treatment beyond UK.
- Regulatory Momentum
- The pace at which other regions approve pediatric use of ITULAZAX® and ACARIZAX®.
- Clinical Impact
- How long-term symptom relief for children affects school performance and quality of life.
Related topics